IMPACT ASSESSMENT MONO- AND COMBINATION ANTIHYPERTENSIVE THERAPY LERCANIDIN AND DILTIAZEM ON CENTRAL BLOOD PRESSURE AND ARTERIAL STIFFNESS IN PATIENTS WITH MILD TO MODERATE ARTERIAL HYPERTENSION
Authors: Rekovets O.L. 
Published: March 2023

Nowadays widely debated search of new methods to reduce cardiovascular risk in thepopulation. Many randomized studies have proven the value of the arterial wall stiffnessin the forecast deterioration of cardiac patients. Therefore, based on these considerationstherapy that improves the elasticity of the arteries may have greater efficacy in preventingmajor cardiovascular events.Purpose – to compare the effectiveness of combination lerсanidipin and diltiazem indifferent dose in patients with mild and moderate arterial hypertension on effects oncentral blood pressure and arterial stiffness.Materials and methods. The study included 123 patients with mild to moderate arterialhypertension, the average office systolic (SBP) / diastolic (DBP) blood pressure – 149,12/ 91,92 ± 1,42 / 0,93 mm Hg. Average age of patients was 51,83 ± 0,86 years. All patientswere divided into group therapy. The first group (n = 20) – diltiazem administered topatients at a dose of 240 mg per day in two divided doses. The second group (n = 20) –patients lerkanidipin 20 mg administered once daily. The third group (n = 22) – patientsintended unfixed combination lerkanidipin 20 mg and 240 mg diltiazem day. The fourthgroup (n = 20) – patients intended unfixed combination lerkanidipin 10 mg and 240 mgdiltiazem day. The fifth group (n = 21) –patients intended unfixed combination lerkanidipin10 mg and 120 mg diltiazem day. The sixth group (n = 20) – patients intended unfixedcombination lerkanidipin 20 mg and 120 mg diltiazem day.All patients at the beginning and end of treatment conducted the following studies:measurement of body weight and height, calculation of body mass index. Measurementoffice SBP, DBP and HR, ambulatory blood pressure monitoring (DMAT), determinationof pulse wave velocity in elastic arteries (PWVe) and muscle (PWVm) types, the definitionof central BP, biochemical blood which included determination of total cholesterol(cholesterol), triglycerides (TG), high density lipoprotein cholesterol (HDL cholesterol),low density lipoprotein cholesterol (LDL-C). Duration of treatment was 1 month.Results. After analyzing all the data, it was found that the сentral blood pressure in alltreatment groups decreased effectively and equally. In the group of 240 mg diltiazemcentral BP significantly decreased by 10.95 mmHg; in group lercanidipin 20 mg 12.18mmHg; in the combination group lercanidipin 20 mg / diltiazem 240 mg 14.13 mm Hg. Inthe combination group lercanidipin 10 mg / diltiazem 240 mg central BP decreased on11.93 mmHg; in the combination group lercanidipin 10 mg / diltiazem 120 mg centralblood pressure decreased on 13.11 mmHg; in the combination group lercanidipin 20 mg /diltiazem 120 mg central blood pressure decreased on 14.82 mmHg. That is, all selectedtreatment regimens were equally effective in reducing central blood pressure. There wasno negative impact on the treatment of all levels of blood lipid spectrum. All treatmentregimen did not significantly affect the average values of indicators characterizing theelastic properties of the arteries (due to short-term observation).Conclusion. Therapy based on both mono and combination lercanidipin and diltiazemwas effective in reducing central blood pressure and did not significantly affect theaverage values of indicators characterizing the elastic properties of the arteries.